Market Snapshot
2018 - 2026
2020
Asia Pacific
North America
5.0 %
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
Hairy cell leukemia is a very rare type of cancer, which accounts for approximately 2%, out of all the leukemia’s. Hairy cell leukemia is characterized by the uncontrolled accumulation of lymphocytes by bone marrow. According to National Organization for Rare Disorders, approximately 600-800 new cases are diagnosed each year in the United States. Most of the affected individuals are males 50 years of age or older. Early diagnosis can help the patients live longer. In recent years, there are advanced diagnostic tests to detect the hairy cell leukemia. First and foremost diagnostic test is a complete blood profile which clearly indicates the total number of lymphocytes, which indicates the disease. Physicians can easily diagnose, if there is an enlarged spleen, by physical examination. One important confirmation test is presence of hairy cells in the blood in the lab tests. Most of the patients also require bone marrow biopsy for confirmation. Diagnosis rate of hairy cell leukaemia is increased during last two-three decades, which is expected to drives the market in the forecast period.
Scope of the Report
As per the scope of the report, Hairy cell leukaemia is a type of blood cancer associated with accumulation of abnormal lymphocytes. Overproduction and accumulation of hairy cells causes a deficiency of normal blood cells.
| By Therapy | |
| Chemotherapy | |
| Targeted Therapy |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| Rest of the World |
Key Market Trends
Chemotherapy Segment is Expected to Register a Significant Growth Over the Forecast Period
Based on therapy, it is segmented into chemotherapy and Targeted Therapy. The key factor contributing to the growth of the chemotherapy segment is the rising incidence of leukemia cases. According to the American Cancer Society estimates, there were around 22,840 death from leukemia in 2019. Many companies are focusing on developing breakthrough products for the treatment of hairy cell leukemia in order to maintain their competitive advantage and penetrate new regional markets. Chemotherapy drugs, specifically purine analogs such as cladribine and pentostatin, are considered as an initial treatment option for most individuals with hairy cell leukemia. Additionally, the increase in funding for companies involved in the research related to hairy cell leukemia is expected to boost the studied market.
To understand key trends, Download Sample Report
North America holds the Largest Share in the Hairy Cell Leukemia Market
The hairy cell leukemia market holds the largest share in North America region due to the presence of high incidence rate, increase in geriatric population and advancements in the treatment of hairy cell leukaemia. According to National Organization for Rare Disorders, Hairy cell leukemia is a rare type of blood cancer, that affects about 6,000 persons in the United States. Europe and the Asia Pacific are followed next after North America owing to the presence of a diversified patient pool and emerging economies in these regions.
To understand geography trends, Download Sample Report
Competitive Landscape
The hairy cell leukemia market is competitive and many of the global players are into the market. For instance - Amgen Inc, AstraZeneca plc, BioGenomics Limited, F. Hoffmann-La Roche Ltd, Incyte Corp, Johnson & Johnson, Merck KGaA, Merck & Co, Inc. and Pfizer Inc. are providing these products across the globe.
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Growing Burden of Leukemia Cases
-
4.2.2 Increase in Diagnosis Rates
-
4.2.3 Growing Geriatric Population
-
-
4.3 Market Restraints
-
4.3.1 Lack of Awareness
-
4.3.2 Limited Health Services in Rural Hospitals
-
-
4.4 Porter's Five Forces Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Therapy
-
5.1.1 Chemotherapy
-
5.1.2 Targeted Therapy
-
-
5.2 Geography
-
5.2.1 North America
-
5.2.1.1 United States
-
5.2.1.2 Canada
-
5.2.1.3 Mexico
-
-
5.2.2 Europe
-
5.2.2.1 Germany
-
5.2.2.2 United Kingdom
-
5.2.2.3 France
-
5.2.2.4 Italy
-
5.2.2.5 Spain
-
5.2.2.6 Rest of Europe
-
-
5.2.3 Asia-Pacific
-
5.2.3.1 China
-
5.2.3.2 Japan
-
5.2.3.3 India
-
5.2.3.4 Australia
-
5.2.3.5 South Korea
-
5.2.3.6 Rest of Asia-Pacific
-
-
5.2.4 Rest of the World
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Amgen Inc.
-
6.1.2 AstraZeneca plc
-
6.1.3 BioGenomics Limited
-
6.1.4 F. Hoffmann-La Roche Ltd
-
6.1.5 Incyte Corp
-
6.1.6 Johnson & Johnson
-
6.1.7 Merck KGaA
-
6.1.8 Merck & Co, Inc.
-
6.1.9 Pfizer Inc.
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Hairy Cell Leukemia Market market is studied from 2018 - 2026.
What is the growth rate of Hairy Cell Leukemia Market?
The Hairy Cell Leukemia Market is growing at a CAGR of 5.0% over the next 5 years.
Which region has highest growth rate in Hairy Cell Leukemia Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Hairy Cell Leukemia Market?
North America holds highest share in 2020.
Who are the key players in Hairy Cell Leukemia Market?
- AstraZeneca plc
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson
- Merck KGaA
- Pfizer Inc.
Are the major companies operating in Hairy Cell Leukemia Market.
